BOOST Pharma的干细胞疗法BT-101在两年内将严重脊髓灰质炎病人的骨折减少了78%,其中一半以上在第二年没有骨折。 BOOST Pharma's stem cell therapy BT-101 reduced fractures by 78% in severe OI patients over two years, with over half having no fractures in year two.

BOOST Pharma报告说,其BOOSTB4试验的两年期后续数据表明,接受BT-101干细胞疗法治疗的脊髓灰质炎重病患者中有一半以上在第二年没有骨折,与预处理水平相比,总体骨折减少78%,第一年则下降70%。 BOOST Pharma reports two-year follow-up data from its BOOSTB4 trial showing that over half of severe OI patients treated with its stem cell therapy BT-101 had no fractures in the second year, with an 78% overall fracture reduction compared to pre-treatment levels—building on a 70% reduction in the first year. 这种疗法使用有异基因的中子细胞干细胞,是首先测试产前和产后管理的第一个疗法,显示对目前没有治疗根部原因的病情具有持续的、改变疾病的潜力。 The therapy, using allogeneic mesenchymal stem cells, is the first to test both prenatal and postnatal administration, showing sustained, disease-modifying potential for a condition with no current root-cause treatments. 审判由欧盟和瑞典资助,在Karolinska研究所赞助下进行。 The trial, supported by EU and Swedish funding, is conducted under Karolinska Institutet’s sponsorship.